evipedia.ai
← Back

40 Hz Ultrasound for Health & Longevity

Evidence Review created on 10/30/2026 using AI4L / Opus 5.5

Also known as: 40 Hz Transcranial Ultrasound Stimulation, 40 Hz TUS, 40 Hz Pulsed Ultrasound, 40 Hz Focused Ultrasound, 40 Hz tFUS, Gamma-Band Ultrasound Stimulation, Gamma Ultrasound, Transcranial Ultrasound Pulsed at 40 Hz

Motivation

40 Hz ultrasound is sound energy above the range of human hearing, aimed through the skull and switched on and off forty times a second. That beat matches a fast brain rhythm tied to attention and memory, a rhythm that tends to weaken in Alzheimer’s disease. The idea is to support this rhythm with a drug-free method that can reach deep memory regions of the brain.

Interest grew from mouse studies asking whether flickering light and clicking sound at the same beat could alter the protein deposits and brain immune cells involved in Alzheimer’s disease. Because light and sound mainly reach the brain’s sensory areas, several laboratories turned to pulsed ultrasound, which travels deeper, and began testing it in mice bred to develop Alzheimer’s-like disease.

This review examines what is known about 40 Hz ultrasound for health-focused adults who want to protect long-term brain health: how it is thought to work, the animal and related human evidence, the safety data, the protocols used so far, and the open questions that ongoing trials are designed to answer.

Benefits - Risks - Protocol - Conclusion

This section lists primary studies and expert commentary that give a high-level view of 40 Hz ultrasound and of the 40 Hz brain-rhythm approach it builds on.

No item from Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io is listed: none has published content on 40 Hz ultrasound, and the only related material found, on FoundMyFitness and Lifespan.io, covers 40 Hz light-and-sound only briefly.

Grokipedia

No Grokipedia article on 40 Hz ultrasound exists.

Examine

No Examine article on 40 Hz ultrasound exists; Examine covers supplements and nutrition rather than device-based brain stimulation.

ConsumerLab

No ConsumerLab article on 40 Hz ultrasound exists; ConsumerLab tests supplements and consumer products and has not reviewed ultrasound brain-stimulation devices.

Systematic Reviews

This section lists systematic reviews of transcranial ultrasound stimulation (TUS, ultrasound delivered through the skull to change brain activity); none analyzes 40 Hz pulsing on its own.

Mechanism of Action

Ultrasound is sound above the range of human hearing; brain-stimulation studies use carrier frequencies of about 0.25–2 MHz (megahertz, million cycles per second). In 40 Hz ultrasound, the carrier is switched on in short bursts 40 times per second (40 hertz, Hz); this pulse repetition frequency (PRF) is what “40 Hz” refers to.

  • Mechanical neuromodulation: low-intensity waves push on neuronal membranes, opening pressure-sensitive ion channels and changing firing without damage.
  • Gamma entrainment: neurons driven at 40 Hz can lock to the beat, strengthening gamma oscillations (fast 30–80 Hz brain rhythms) generated by fast-spiking inhibitory interneurons that release GABA (gamma-aminobutyric acid, the brain’s main calming messenger); these rhythms weaken in Alzheimer’s-model mice (Park 2021).
  • Glial response: in mice, 40 Hz pulsing recruited microglia to plaques and lowered Aβ (Bobola 2020) and damped RIPK1 (receptor-interacting protein kinase 1, an enzyme that triggers inflammatory cell death) and NF-κB (a master switch for inflammatory genes) signaling (Yi 2026).
  • Competing explanations: pulsed ultrasound is heard through the skull at its pulse rate, so part of any effect may come from sound reaching the hearing pathway (Braun 2020); whether outside 40 Hz drive engages the brain’s own gamma rhythm is disputed (Soula 2023). Ultrasound at other pulse rates may act instead through blood vessels via endothelial nitric oxide synthase (eNOS, an enzyme that makes the vessel-widening gas nitric oxide) (Shindo 2024, by the developer group of device maker Sound Wave Innovation).

Half-life and metabolism do not apply to physical energy.

Historical Context & Evolution

  • Original use: ultrasound entered medicine in the mid-20th century for imaging and, at high intensity, tissue destruction; low-intensity brain stimulation came later.
  • Path to 40 Hz: in 2016, light flickering at 40 Hz lowered Aβ and recruited microglia in mouse visual cortex, by Cognito Therapeutics’ co-founders (Iaccarino 2016; the paper carries author corrections, Iaccarino 2018 and Iaccarino 2024). Because light reaches mainly sensory cortex, a University of Washington group pulsed focused ultrasound at 40 Hz to reach the hippocampus (the brain’s memory hub) and found plaque burden 47% lower than sham after five days (Bobola 2020). Korean and Chinese groups followed (Park 2021, Chen 2025).
  • Why it drew longevity interest: the approach is drug-free, reaches deep memory regions and targets a rhythm fading early in Alzheimer’s disease.
  • Neighboring human work: 40 Hz light-and-sound entered human pilots led by the same group (Chan 2022), whose device company sponsors its pivotal trial (NCT05637801). Whole-brain pulsed ultrasound at another pulse rate was tested by its developers (Shimokawa 2022); its lead author is affiliated with Sound Wave Innovation, the pivotal trial’s sponsor (NCT05983575). An uncontrolled focused-ultrasound dementia report (Nicodemus 2019) carries an Alzheimer’s & Dementia expression of concern over unsupported statements and possible undisclosed patent interests.
  • Open debate: 40 Hz light failed to entrain native gamma or reduce plaques in one laboratory (Soula 2023), while another linked 40 Hz light-and-sound to brain fluid clearance (Murdock 2024). No human study of 40 Hz ultrasound has been published.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human trial has tested 40 Hz ultrasound on any clinical endpoint, and human outcome data exist only for ultrasound at other pulse rates or for 40 Hz light-and-sound, which are indirect evidence.

Medium 🟩 🟩

No benefit reaches Medium: the only controlled human trials used different ultrasound protocols or a different 40 Hz delivery route, so every human outcome is indirect evidence capped at Low.

Low 🟩

Slower Cognitive Decline in Early Alzheimer’s Disease ⚠️ Conflicted

Human evidence is indirect (other pulse rates): a small randomized whole-brain trial trended non-significantly (Shimokawa 2022); a larger trial, sponsored by device maker Storz Medical, missed its primary endpoint (Matt 2025). 40 Hz ultrasound improved maze memory only in mice (Chen 2025, Yi 2026). Net reading: no reliable human benefit.

Magnitude: At 72 weeks, 5 of 10 ultrasound versus 0 of 5 placebo participants had no worsening of the ADAS-J cog score (Alzheimer’s Disease Assessment Scale, Japanese cognitive subscale), P = 0.053 (P, the probability of a result this large arising by chance); the score difference itself was not significant, P = 0.257 (Shimokawa 2022). In Matt 2025, the CERAD total score (a standard dementia test battery) rose 2.22 points with active versus 1.00 with sham stimulation, P = .68.

Fewer Depressive Symptoms ⚠️ Conflicted

Evidence is indirect: transcranial pulse stimulation (TPS, short ultrasound shock pulses) at 5 pulses per second. In one randomized crossover trial in Alzheimer’s disease, depression scores fell more with active than sham stimulation in completers treated as planned, not in all randomized participants (Matt 2025). Net reading: an uncertain signal.

Magnitude: On the BDI-II (Beck Depression Inventory-II, a 0–63 depression scale), scores fell from 7.27 to 5.27 after active versus 6.70 to 6.22 after sham TPS at 3 months (per-protocol analysis, completers treated as planned; P = .008); the intention-to-treat analysis (all randomized participants) was not significant, and the source gives no between-group estimate with a 95% CI (confidence interval, the range likely to contain the true effect).

Speculative 🟨

Lower Amyloid Plaque Burden ⚠️ Conflicted

Plaques fell in two mouse studies (Bobola 2020, Yi 2026); a third’s abstract-reported fall was non-significant (P = 0.051) (Park 2021); a modified protocol failed in older mice (Phutirat 2026). Net reading: young models only.

Restored Gamma Rhythms and Brain Network Coupling

In Alzheimer’s-model mice, 40 Hz ultrasound raised gamma power and rhythm coupling (Park 2021), with gains persisting five days after stimulation (Chen 2025). These are unvalidated biomarkers from animal work only.

Lower Brain Inflammation

In female 5×FAD mice, 14 days of 40 Hz ultrasound lowered inflammatory signaling proteins (interleukin-6, interleukin-1β, tumor necrosis factor-α) and RIPK1/NF-κB signaling (Yi 2026). Single-laboratory mouse data only.

Enhanced Brain Waste Clearance

40 Hz light-and-sound boosted glymphatic flow (fluid-driven waste clearance) in mice (Murdock 2024), and 40 Hz skull vibration raised brain-fluid coupling in people (Kong 2025). Extension to ultrasound is mechanistic only.

Benefit-Modifying Factors

  • Genetic variants: APOE4 (a variant of the cholesterol-transport gene APOE that raises Alzheimer’s risk) has not been studied with 40 Hz ultrasound; in 40 Hz light-and-sound users, late-onset but not early-onset Alzheimer’s patients kept strong entrainment (Chan 2025).
  • Baseline biomarkers: plaque load matters; a modified ultrasound protocol cleared plaques in younger but not in older, more plaque-laden mice (Phutirat 2026). Amyloid-negative healthy adults have no tested benefit.
  • Sex: one awake-mouse study used only females (Yi 2026), another only males (Chen 2025), and a review names biological sex as a source of variable 40 Hz responses (Qi 2026).
  • Pre-existing conditions: hearing or vision loss can blunt light-and-sound entrainment; ultrasound bypasses the sense organs, an argued but untested advantage (Park 2021). Disease stage likely shapes response, per a review (Qi 2026).
  • Age: in the TPS trial, only patients aged 70 or younger improved significantly (Matt 2025); older mice showed no plaque change (Phutirat 2026), suggesting weaker response at the older end of the range.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human study of 40 Hz ultrasound has recorded adverse events, and human adverse-event data exist only for ultrasound at other pulse rates, which is indirect evidence.

Medium 🟥 🟥

No risk reaches Medium: human adverse-event data come from ultrasound protocols that differ in pulse rate and intensity, so they are indirect evidence capped at Low.

Low 🟥

Transient Headache, Neck Pain and Scalp Sensations ⚠️ Conflicted

A systematic review (Sarica 2022) and a symptom survey (Legon 2020) describe mild, short-lived headache, neck pain, scalp tingling and sleepiness; the evidence is indirect (not 40 Hz). Randomized trials recorded symptoms under both active and sham (Matt 2025) or none (Shimokawa 2022). Net reading: mild and rarely attributable.

Magnitude: Mild symptoms in 14 of 425 participants (3.4%) pooled across human transcranial ultrasound studies; no comparison-group rate was reported (Sarica 2022).

Audible Buzzing During Stimulation

Pulsed ultrasound is conducted through the skull as sound at its pulse rate, and participants could hear stimulation (Braun 2020). Evidence is indirect: the study used 1,000 Hz modulation, not 40 Hz. A 40 Hz pulse rate lies in the audible range and also undermines blinding.

Magnitude: 16 of 18 healthy participants reported hearing a high-pitched tone they linked to stimulation; with masking sound through earphones, group detection fell to chance, though 3 of 18 still detected it; no control group (Braun 2020).

Speculative 🟨

Microbleeds and Tissue Injury at High Intensity

A systematic review found microhemorrhages and cell damage in animals exposed above safety limits (Pasquinelli 2019); a low-intensity 40 Hz mouse study found no microbleed increase (Park 2021). The basis is animal-only.

Skull and Scalp Heating

Heating rises with intensity and carrier frequency; the founding mouse protocol used 2 MHz (Bobola 2020). A consortium including device makers set consensus temperature limits (Aubry 2025). The basis is biophysical only.

Rise in Soluble Amyloid-Beta

Two weeks of 40 Hz ultrasound lowered insoluble but raised soluble Aβ42 (the 42-unit form, possibly more toxic) in 5×FAD mice (Park 2021). The basis is a single mouse study.

Reduced Vessel Signaling in Older Brains

In older 5×FAD mice, a modified ultrasound protocol shifted eNOS away from vessels, which the authors flag as a possible ischemia (reduced blood supply) risk (Phutirat 2026). The basis is animal-only.

Risk-Modifying Factors

  • Genetic variants: APOE4 favors amyloid deposits in vessel walls and microbleeds; its interaction with ultrasound is unstudied, and any added bleeding risk is inferred from animal microhemorrhage data in a systematic review (Pasquinelli 2019).
  • Baseline biomarkers: existing microbleeds or iron deposits on susceptibility-weighted imaging (SWI, an iron-sensitive magnetic resonance imaging (MRI) brain scan) mark fragile vessels and are the main baseline safety flag.
  • Sex: no sex-specific risk data exist; skull thickness, which governs how much ultrasound passes through, varies between individuals (Shindo 2024).
  • Pre-existing conditions: epilepsy, cerebral amyloid angiopathy (amyloid in vessel walls causing bleeds), prior brain hemorrhage, skull defects and metal implants raise inferred risk; none has been studied with 40 Hz ultrasound.
  • Age: older brains may respond differently, as aged mice showed vessel-signaling shifts (Phutirat 2026); thicker, denser older skulls may absorb more energy, and age-related hearing loss reduces the audible buzz.

Key Interactions & Contraindications

Documented interactions:

  • Ultrasound contrast agents (perflutren lipid microspheres, sulfur hexafluoride microspheres): Avoid. In people, these microbubbles plus focused ultrasound opened the blood–brain barrier (the vessel lining that shields the brain) (Meng 2023); consequence: unintended barrier opening; separating sessions from contrast scans by a day is common practice.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Anticoagulants (drugs that slow blood clotting) and antiplatelet drugs (drugs that stop platelets from clumping) (warfarin, apixaban, clopidogrel): additive bleeding tendency inferred from microhemorrhages in animals exposed above safety limits; consequence: brain microbleeds. Baseline SWI and conservative intensity reduce the concern.
  • Over-the-counter antiplatelet pain relievers (aspirin, ibuprofen, naproxen): platelet inhibition inferred to add to ultrasound-related microvascular stress; consequence: microbleeds. Omitting non-essential doses on session days is a common precaution.
  • GABA-enhancing sedatives (lorazepam, alprazolam, zolpidem): gamma rhythms depend on GABA-releasing interneurons, so sedation is inferred to blunt 40 Hz entrainment; consequence: reduced effect. Scheduling sessions away from peak sedative effect avoids this.
  • Seizure-threshold-lowering drugs (bupropion, tramadol, clozapine): additive cortical excitability inferred from excitatory rhythmic stimulation; consequence: seizure. Neurological review before use mitigates this.
  • Anti-amyloid antibodies (infused drugs that clear amyloid plaques) (lecanemab, donanemab): additive microglial and vascular effects inferred; consequence: amyloid-related imaging abnormalities (ARIA, brain swelling or microbleeds on MRI). MRI monitoring applies if both are used.
  • Antiplatelet supplements (fish oil, Ginkgo biloba, vitamin E): additive platelet inhibition inferred; consequence: microbleeds. Pausing high doses around sessions is a common precaution.
  • Supplements with additive effects: none identified; no supplement is known to strengthen 40 Hz entrainment.
  • Other 40 Hz stimulation (light-and-sound devices, 40 Hz electrical stimulation): additive entrainment inferred from a mouse study combining 40 Hz ultrasound and light (Gao 2026); consequence: an untested, stronger stimulation dose. Avoiding same-session stacking outside research mitigates this.

Populations who should avoid 40 Hz Ultrasound:

  • Compromised thermoregulation, vascular vulnerabilities, or recent ultrasound contrast agents: consensus non-significant-risk levels, from a consortium including device makers, explicitly exclude these groups (Aubry 2025).
  • Skull defects, craniotomy (surgical skull opening), or metal implants in the beam path (aneurysm clips, deep brain stimulation leads, cochlear implants): inferred from beam distortion and local heating at bone gaps and metal; no human data.
  • Epilepsy or prior unprovoked seizure: inferred from excitatory, rhythmic brain stimulation; no human data.
  • Cerebral amyloid angiopathy, prior brain hemorrhage, or microbleeds on baseline MRI: inferred from animal microhemorrhages in a systematic review (Pasquinelli 2019); no human data.
  • Pregnancy: inferred from the absence of any safety data and fetal sensitivity to heating; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Capped mechanical and thermal exposure: mechanical index (MI, a bubble-formation risk measure) is kept ≤1.9 and temperature rise ≤2 °C, the consensus non-significant-risk levels of a consortium including device makers (Aubry 2025); prevents heating and tissue injury.
  • Baseline brain MRI with SWI: screens for microbleeds, prior hemorrhage and vessel amyloid before the first session; mitigates the bleeding risk inferred from animal data.
  • Low carrier frequencies: human protocols in a systematic review used 220–650 kHz (kilohertz, thousand cycles per second) (Wang 2025), where the skull absorbs less energy than at the 2 MHz of mouse work; mitigates skull and scalp heating.
  • Auditory masking: a masking sound is played through earphones during sessions (Braun 2020); mitigates the audible buzz and its distortion of blinded comparisons.
  • Symptom questionnaire after each session: symptoms are recorded on a structured form, e.g., the Participant Report of Symptoms (Legon 2020); use stops and medical evaluation follows for headache lasting over 24 hours or any new neurological symptom; mitigates missed injury.
  • Calibrated, documented devices only: devices report full acoustic output per standards of the International Transcranial Ultrasonic Stimulation Safety and Standards consortium (ITRUSST), whose members include device makers (Martin 2024); prevents overexposure from unverified equipment.
  • Separation from contrast agents: no session on the day of a contrast-enhanced ultrasound; prevents unintended blood–brain barrier opening, which microbubbles plus focused ultrasound produce in people (Meng 2023).

Therapeutic Protocol

No human 40 Hz ultrasound protocol exists. Each dose below is cited to the study that used it; other parameters without a citation (timing, cycling, session structure) reflect common practice.

  • No human regimen: no clinic or practitioner offers 40 Hz ultrasound; published protocols come from laboratories led by Pierre Mourad (Seattle), Tae Kim (Gwangju), Lili Niu (Shenzhen) and Yi Yuan (Qinhuangdao).
  • Focused high-peak protocol (Mourad): 2.0 MHz carrier, 40 Hz PRF, 400-microsecond pulses, spatial-peak pulse-average intensity (peak power per area within each pulse) 190 W/cm², 1 hour daily for 5 days in sedated mice (Bobola 2020).
  • Unfocused low-intensity protocol (Kim): 300 kHz carrier, 40 Hz PRF, 3-millisecond pulses, 1.2 W/cm² peak and 14.4 mW/cm² time-averaged intensity (averaged over pauses), 10 seconds on and 30 seconds off, 2 hours daily for 14 days (Park 2021).
  • Wearable awake protocol (Niu): 14 days at 2.14 W/cm² gave the best memory outcome among tested intensities in female mice (Yi 2026).
  • Competing human approaches: whole-brain pulsed ultrasound at 0.5 MHz, 32 cycles, 0.25 W/cm², 1 hour three times weekly, repeated every 3 months (Shimokawa 2025); or 40 Hz light-and-sound 1 hour daily (Chan 2022).
  • Time of day: no data for 40 Hz ultrasound; sleep-timed ultrasound during naps is under test (NCT07866768), and most mouse protocols ran under anesthesia, though two stimulated awake mice (Chen 2025, Yi 2026).
  • Persistence of effect: ultrasound leaves no residue to clear; gamma enhancement persisted 5 days after stimulation in mice (Chen 2025), and microglial activation faded within 5 daily sessions (Bobola 2020).
  • Single versus split sessions: delivered as one daily session built from short on/off blocks (Park 2021); no study compared splitting the daily dose.
  • Genetic polymorphisms: no study has stratified by APOE4 or other variants; no genotype-guided protocol exists.
  • Sex differences: female-only (Yi 2026) and male-only (Park 2021) mouse studies prevent comparison; no sex-specific protocol exists.
  • Age: a 5-day course in older mice failed where a 3-day course worked in younger mice, suggesting age-dependent dosing (Phutirat 2026).
  • Baseline biomarkers: human ultrasound trials enroll by amyloid status, using plasma p-tau217 (a blood marker of Alzheimer’s pathology) or amyloid scans (NCT07573982); amyloid-negative adults are untested.
  • Pre-existing conditions: hearing loss does not block ultrasound, an argued advantage over light-and-sound (Park 2021); disease stage likely shapes response, per a review (Qi 2026); skull thickness changes the delivered dose (Shindo 2024); trials model heads from MRI (NCT07298876).

Discontinuation & Cycling

  • Duration: mouse courses lasted 5–14 days; no lifelong regimen is defined. The related human whole-brain ultrasound trial used repeated sessions over 72 weeks (Shimokawa 2022).
  • Withdrawal effects: none described; there is no known physiological basis for dependence or rebound after stopping.
  • Tapering: not applicable; sessions can stop at any point without stepping down.
  • Cycling: microglial activation faded within 5 daily sessions (Bobola 2020), suggesting intermittent courses; related human ultrasound used sessions every 3 months (Shimokawa 2025).
  • Durability: gamma changes persisted 5 days after stimulation in mice (Chen 2025); persistence beyond that is unknown.

Sourcing and Quality

  • No consumer product with data: no commercially sold 40 Hz ultrasound device has published safety or efficacy data; all evidence comes from laboratory systems.
  • Misleading “40 Hz” labels: many products deliver audible 40 Hz sound or flicker, and ultrasonic cleaners run near 40 kHz; neither is 40 Hz-pulsed transcranial ultrasound.
  • Acoustic output documentation: credible systems report carrier frequency, PRF, pulse duration, intensities and MI following ITRUSST standards (Martin 2024; the consortium includes device makers), backed by calibrated hydrophone (underwater microphone) measurements.
  • Research access: registered trials use investigational devices under ethics oversight, the only quality-controlled route (NCT07239310, NCT07298876).
  • Reputable sources: academic groups (University of Washington, Gwangju Institute of Science and Technology, Shenzhen Institutes of Advanced Technology) and research-hardware makers such as Sonic Concepts (NCT07691918) and Brainsonix (NCT04770350).

Practical Considerations

  • Time to effect: mouse plaque and rhythm changes appeared after 5–14 daily sessions (Bobola 2020, Park 2021); human trials of related ultrasound measured cognition at 3 months to 72 weeks (Matt 2025, Shimokawa 2022).
  • Common pitfalls: confusing 40 Hz sound, 40 kHz ultrasound and 40 Hz-pulsed ultrasound; equating mouse plaque clearance with human cognitive benefit; ignoring the audible-buzz confound; using uncalibrated devices.
  • Regulatory status: human ultrasound brain stimulation for cognition is tested with investigational devices, such as the Neuclare device (NCT07239310); transcranial pulse stimulation has carried a European CE mark for Alzheimer’s disease since 2018 (Matt 2025). No marketed 40 Hz ultrasound product was identified.
  • Cost and accessibility: access is mainly through trials; MRI-guided targeting and research hardware make private use expensive and rare.
  • Blinding and expectation: audible pulses and scalp sensations make sham control difficult, so personal trials cannot separate effect from expectation (Braun 2020).

Interaction with Foundational Habits

  • Sleep: possibly potentiating. Waste clearance peaks during sleep, and trials pair ultrasound with naps or target sleep quality (NCT07866768, NCT07298876); an early dementia ultrasound report encouraged sleep during sessions (Nicodemus 2019). No sleep data exist for 40 Hz ultrasound.
  • Nutrition: none known. A physical energy causes no nutrient depletion, and no food is known to strengthen 40 Hz entrainment; brain-healthy dietary patterns act independently.
  • Exercise: none documented. Exercise supports cognition independently; no study has tested timing of ultrasound around workouts or any blunting of training adaptations.
  • Stress management: indirect. Rare anxiety reports occurred in human ultrasound studies (Legon 2020), while the TPS trial noted lower depression scores (Matt 2025). No cortisol data exist; sessions require stillness, which suits paired relaxation practice.

Monitoring Protocol & Defining Success

Baseline testing before any research use includes a brain MRI with SWI to exclude microbleeds and vessel amyloid, a cognitive screen such as the Montreal Cognitive Assessment (MoCA, a 30-point screening test), plasma p-tau217 and amyloid-beta 42/40 ratio to define amyloid status, a hearing check documenting whether the pulses are audible, and, where available, a resting EEG (electroencephalography, scalp recording of brain rhythms) measuring the 40 Hz response.

Ongoing monitoring follows trial-style timepoints: a symptom questionnaire after every session; repeat cognitive testing at 2, 6 and 10 weeks, as in NCT07298876; plasma biomarkers at the end of each course, then every 6–12 months; and a repeat MRI after the first course or with any new neurological symptom.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Brain MRI with SWI (microbleed count) No established target; track new microbleeds against own baseline scan Safety check: new microbleeds stop use Inferred from animal microhemorrhage data in a systematic review (Pasquinelli 2019); compare scans from the same scanner and sequence
Plasma p-tau217 No established target; track change from own baseline Expected to change: fell in two long-term 40 Hz light-and-sound users Chan 2025; assay-specific diagnostic cutoffs are not treatment targets; use the same laboratory each time
Plasma Aβ42/40 ratio No established target; track change from own baseline Expected to change if amyloid clearance occurs Measured as an outcome in NCT07298876; best paired with p-tau217; assay-dependent
Resting EEG 40 Hz power No established target; track change from own baseline Expected to change: rose after 14 days in mice Park 2021; record at the same time of day, with masking sound to avoid auditory artifact

Qualitative markers:

  • Headache, neck pain or scalp warmth after sessions
  • Loudness of the perceived buzz during sessions
  • Sleep quality and daytime alertness
  • Memory and word-finding in daily life
  • Mood and anxiety

Emerging Research

  • First human 40 Hz ultrasound study (no NCT ID): a registry search on 10/30/2026 found no registered trial of 40 Hz-pulsed ultrasound in people. A positive sham-controlled trial would lift benefits above Speculative; a null trial would undercut the mouse findings.
  • Neuclare cortical ultrasound (NCT07239310): randomized, double-blind, 138 adults with mild cognitive impairment or prodromal (earliest symptomatic) Alzheimer’s disease; primary endpoint Trail Making Test A time at week 5; ongoing to January 2027; pulse rate not stated. Positive: strengthens indirect cognitive evidence; null: weakens it.
  • Hippocampal ultrasound for sleep and memory (NCT07298876): 20 adults aged 60–85, 500 kHz versus sham for 2 weeks; sleep index, delayed recall, p-tau217 and Aβ outcomes; ongoing to May 2027. Positive: supports a sleep-memory benefit; null: tempers it.
  • Thalamic (deep brain relay hub) ultrasound during naps (NCT07866768): 28 amyloid-positive adults aged 65+ with mild cognitive impairment, head-worn device versus unfocused ultrasound over 10 naps; safety primary; ongoing to January 2028. Positive: supports a sleep-clearance route; null: weakens it.
  • Ultrasonic debris clearance (NCT07573982): 15 amyloid-positive adults, 250 kHz broad exposure, 8 sessions over 4 weeks versus sham; safety primary; ongoing to July 2027. Positive: supports waste-clearance benefit; null: weakens it.
  • LIPUS-AD pivotal trial (NCT05983575): 220 early-Alzheimer’s patients, whole-brain pulsed ultrasound versus placebo for 72 weeks; registered completion July 2026 has passed, status “active, not recruiting”, no results posted. Positive: first confirmed ultrasound cognitive benefit; null: weakens the Low cognition item.
  • HOPE 40 Hz light-and-sound trial (NCT05637801): 673 people with Alzheimer’s disease; completed August 2026, no results posted. Positive: strengthens the 40 Hz rationale; null: weakens the gamma-entrainment premise behind 40 Hz ultrasound.
  • Transcranial ultrasound for frailty (NCT04770350): open-label, 50 adults with age-related frailty, sponsored by Neurological Associates of West Los Angeles; registered completion December 2024 has passed, status unknown, no results posted. Positive: first longevity-relevant signal; null: leaves frailty benefit unsupported.
  • Does 40 Hz drive engage native gamma? Mouse data conflict: light-only flicker recorded with deep-brain probes found no native gamma or plaque change (Soula 2023), while combined light-and-sound promoted brain fluid clearance (Murdock 2024); stimulus type and outcome measured differ. Either resolution could strengthen or weaken the premise.
  • Masked sham designs: future trials must mask the audible 40 Hz buzz (Braun 2020); otherwise benefits may reflect 40 Hz sound rather than ultrasound.

Conclusion

40 Hz ultrasound means sound waves too high to hear, sent into the head in bursts forty times a second to drive a fast brain rhythm that weakens in Alzheimer’s disease. For health-focused adults protecting the aging brain, the appeal is a drug-free method reaching deep memory areas that light and audible sound cannot.

The evidence is almost entirely animal-based. Several laboratories report that mice bred to develop Alzheimer’s-like disease had fewer protein deposits, less brain inflammation and better maze memory after short daily courses. One study in older mice saw no such change, and separate work questions whether rhythmic outside stimulation engages the brain’s own rhythm at all. No person has yet received this specific treatment in a published study. Human trials of related ultrasound methods in early Alzheimer’s disease show small, uncertain effects on thinking, and the largest controlled one did not meet its main goal.

The known downsides in people come from related ultrasound methods: mild, short-lived headache, neck discomfort and scalp sensations, plus an audible buzz that makes fair comparison with a placebo treatment hard. Heating, tiny brain bleeds and shifts in disease proteins appear only in animals or at higher energies.

Much nearby human evidence comes from groups developing or selling devices, and one early human report now carries a journal warning about undisclosed financial interests. Overall, benefits for healthy longevity are unproven, risks at careful settings look small but poorly measured, and the method remains a research tool.

Top - Benefits - Risks - Protocol